Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: "New targets for the treatment of follicular lymphoma"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:New targets for the treatment of follicular lymphoma | Journal of Hematology Oncology BioMed Central Open Access New targets for the treatment of follicular lymphoma NishantTageja1 Subhash Padheye2 Prasad Dandawate2 Ayad Al-Katib3 and Ramzi M Mohammad 3 Address Department of Internal Medicine Wayne State University School of Medicine Detroit MI- 48201 USA 2Drug design and Molecular Medicine Research group Department of Chemistry D.Y. Patil University Pune India and 3Department of Internal Medicine Division of Hematology Oncology Wayne State University School of Medicine Detroit Michigan USA Email NishantTageja - ntageja@med.wayne.edu Subhash Padheye - sbpadhye@hotmail.com Prasad Dandawate - dandawate.prasad@gmail.com Ayad Al-Katib - aalkati@med.wayne.edu Ramzi M Mohammad - mohammar@karmanos.org Corresponding author Published 23 December 2009 Received 20 October 2009 Journal of Hematology Oncology 2009 2 50 doi 10.1186 1756-8722-2-50 Accepted 23 December 2009 This article is available from http www.jhoonline.Org content 2 1 50 2009 Tageja et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma FL . Development of newer treatment approaches have improved the outlook for many individuals with these disorders however with these advances come new questions. Given the long-term survival of patients with FL drugs with favourable side-effect profile and minimal long-term risks are desired. FL is incurable with current treatment modalities. It often runs an indolent course with multiple relapses and progressively shorter intervals of remission. The identification of new targets and development of novel targeted therapies is .